I can highlight three of those investments because they're each very interesting in terms of capability that's possible for Canada in the future.
For example, Medicago is working on a unique virus-like platform based in plants. Obviously it has been supported to build out its productive capacity, which, when it comes online—and obviously presuming there's a successful process to approve the vaccine—would provide a very considerable amount of future biomanufacturing capability for Canada, based on the novel vaccine platform technology that Medicago has been developing for many years.
PNI was mentioned as well as a leader in terms of the lipid nanoparticles, the new type of mRNA vaccine, in an area where there's significant Canadian leadership, in fact, and a long-standing leadership of companies in Canada in this space. It is new and it obviously has been the news of COVID-19 in terms of technological development that these new types of vaccines are very important in terms of responsiveness. That capability will be there in the future for Canada.
VBI Vaccines is working on a platform that they're intending to address a broader spectrum of coronavirus as well, including SARS and MERS. Again, it's another very important Canadian technology developed in Ottawa at their research centre and will be able to be advanced for the future.
These do obviously give a sense of the capability in Canada and, of course, the funding that has been provided will allow those capabilities to be advanced considerably in this time.